TheraSphere HUD For Treatment of Unresectable HCC

Trial Information

TheraSphere HUD For Treatment of Unresectable HCC

Surgical resection of the affected portion of the liver offers the best chance for
disease-free survival in patients with primary liver cancer (hepatocellular carcinoma
(HCC)). Unfortunately, most of these patients present with disease that is not amenable to
surgery (multifocal disease) or have other medical contraindications to surgery (limited
hepatic reserve related to advanced cirrhosis or chronic hepatitis). Fewer than 15% of HCC
patients are suitable surgical candidates. The objective of treatment with TheraSphere is to
selectively administer a potentially lethal dose of radioactive material to cancerous tissue
in the liver of patients with HCC. This type of regional therapy may have several advantages
over systemically administered treatments and may also be of value as a 'bridging' treatment
for HCC patients awaiting a donor organ for liver transplantation.

Inclusion Criteria:

- Patients over 18 years of age, of any race or sex, who have histologic proof of
primary cancer to the liver, who are able to give informed consent, will be eligible.

- Patients must have an ECOG Performance Status score of greater than or equal to 2,
with a life expectancy of > 3 months, non-pregnant with an acceptable contraception
in premenopausal women.

- The histopathology confirmation criterion may be waived in patients with a
radiographically identifiable liver mass, known laboratory or clinical risk factors
for cancer or elevated tumor markers such as AFP (clinical diagnosis).

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.